Skip to main content

Free Content Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

Download Article:
(PDF 292.6904296875 kb)
BACKGROUND: Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration.

METHODS: Forty-eight patients with smear-positive tuberculosis (63% male; 54.7 ± 9.9 kg; 30.7 ± 10.8 years) were randomly assigned to receive delamanid 100, 200, 300 or 400 mg daily for 14 days. Colony forming units (cfu) of M. tuberculosis were counted on agar plates from overnight sputum collections to calculate early bactericidal activity (EBA), defined as fall in log10 cfu/ml sputum/day.

RESULTS: The EBA of delamanid was monophasic and not significantly different between dosages; however, more patients receiving 200 mg (70%) and 300 mg (80%) experienced a response of ≥0.9 log10 cfu/ml sputum decline over 14 days than those receiving 100 mg (45%) and 400 mg (27%). The average EBA of all dosages combined (0.040 ± 0.056 log10 cfu/ml sputum/day) was significant from day 2 onward. Delamanid exposure was less than dosage-proportional, reaching a plateau at 300 mg, likely due to dose-limited absorption. Moderate but significant correlation was found between Cmax and EBA, indicating exposure dependence. Delamanid was well tolerated without significant toxicity.

CONCLUSIONS: Delamanid at all dosages was safe, well tolerated and demonstrated significant exposure-dependent EBA over 14 days, supporting further investigation of its pharmacokinetics and anti-tuberculosis activity.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: OPC-67683; delamanid; early bactericidal activity; tuberculosis

Document Type: Regular Paper

Affiliations: 1: Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa 2: Centre for TB Research Innovation, University of Cape Town Lung Institute, Cape Town, South Africa 3: Otsuka Frankfurt Research Institute GmbH, Frankfurt am Main, Germany 4: Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland, USA 5: Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa

Publication date: 2011-07-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more